1
|
Mandelblatt J, Meza R, Trentham-Dietz A, Heckman-Stoddard B, Feuer E. Using simulation modeling to guide policy to reduce disparities and achieve equity in cancer outcomes: state of the science and a road map for the future. J Natl Cancer Inst Monogr 2023; 2023:159-166. [PMID: 37947330 PMCID: PMC11009490 DOI: 10.1093/jncimonographs/lgad033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Accepted: 09/10/2023] [Indexed: 11/12/2023] Open
Affiliation(s)
- Jeanne Mandelblatt
- Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
- Georgetown Lombardi Comprehensive Cancer Center, Cancer Prevention and Control Program, Washington, DC, USA
- Georgetown Lombardi Institute for Cancer and Aging Research, Georgetown University Medical Center, Washington, DC, USA
| | - Rafael Meza
- Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
| | - Amy Trentham-Dietz
- Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI, USA
- Carbone Cancer Center, University of Wisconsin–Madison, Madison, WI, USA
| | - Brandy Heckman-Stoddard
- Breast and Gynecologic Cancer Research Program, Division of Cancer Prevention, National Cancer Institute at the National Institutes of Health, Bethesda, MD, USA
| | - Eric Feuer
- Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute at the National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
2
|
Sahasrabuddhe VV, Castle PE, Schiffman M, Wentzensen N, Heckman-Stoddard B, Arbyn M. Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'. Int J Cancer 2022; 151:484-487. [PMID: 35377490 DOI: 10.1002/ijc.34013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Accepted: 03/24/2022] [Indexed: 11/06/2022]
Affiliation(s)
| | - Philip E Castle
- Division of Cancer Prevention, U.S. National Cancer Institute, Rockville, Maryland, USA.,Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, Maryland, USA
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, Maryland, USA
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, Maryland, USA
| | | | - Marc Arbyn
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.,Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| |
Collapse
|
3
|
Arbyn M, Castle PE, Schiffman M, Wentzensen N, Heckman-Stoddard B, Sahasrabuddhe VV. Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening. Int J Cancer 2022; 151:308-312. [PMID: 35179777 DOI: 10.1002/ijc.33967] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 01/02/2022] [Accepted: 01/18/2022] [Indexed: 11/12/2022]
Abstract
We conducted a meta-analysis of test agreement/concordance between human papillomavirus (HPV) testing in self-collected versus clinician-collected samples in 26 studies (10,071 participants) updating a previous meta-analysis on accuracy for cervical precancer. Pooled overall agreement was 88.7% (95%CI: 86.3%-90.9%), positive agreement was 84.6% (95%CI: 79.9%-88.7%), negative agreement was 91.7% (95%CI: 89.1%-94.0%), and kappa was 0.72 (95%CI: 0.66-0.78). Subgroup meta-analyses suggested higher overall agreement for target amplification-based DNA assays (90.4%) compared to signal amplification-based DNA assays (86.7%) (p=0.175) or RNA assays (82.3%) (p<0.001). HPV test agreement/concordance targets may provide criteria to extend existing validations towards alternative sampling approaches and devices/storage media. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Marc Arbyn
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.,Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Philip E Castle
- Division of Cancer Prevention, U.S. National Cancer Institute, Rockville, Maryland, USA.,Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, Maryland, USA
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, Maryland, USA
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, Maryland, USA
| | | | | |
Collapse
|
4
|
Lee CG, Heckman-Stoddard B, Dabelea D, Gadde KM, Ehrmann D, Ford L, Prorok P, Boyko EJ, Pi-Sunyer X, Wallia A, Knowler WC, Crandall JP, Temprosa M. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2021; 44:2775-2782. [PMID: 34697033 PMCID: PMC8669534 DOI: 10.2337/dc21-1046] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Accepted: 09/20/2021] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. RESEARCH DESIGN AND METHODS From 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those originally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively. RESULTS Over a median of 21 years (interquartile range 20-21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality. CONCLUSIONS Cancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, neither strategy reduced all-cause, cancer, or cardiovascular mortality rates.
Collapse
Affiliation(s)
- Christine G Lee
- Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
| | - Brandy Heckman-Stoddard
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD
| | - Dana Dabelea
- Department of Epidemiology and Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO
| | | | | | - Leslie Ford
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD
| | - Philip Prorok
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD
| | - Edward J Boyko
- Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle
| | | | - Amisha Wallia
- Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - William C Knowler
- Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ
| | - Jill P Crandall
- Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, Bronx, NY
| | | | | | | |
Collapse
|
5
|
Brofsky E, House M, Heckman-Stoddard B, Nokta M, Gopal S, Sahasrabuddhe V. Abstract 20: Development of International Cancer Research Partnerships Through the NCI US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet). Cancer Epidemiol Biomarkers Prev 2021. [DOI: 10.1158/1538-7755.asgcr21-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Purpose: Persons living with HIV have elevated risks of HPV-related cervical, anogenital, and oropharyngeal cancers. Yet, research on optimization and implementation of prevention interventions (prophylactic HPV vaccination, cervical and anogenital cancer screening and triage, and precancer therapeutics) for HPV-related cancers among persons living with HIV has been limited. With a goal to expand this evidence, and building on strong academic research partnerships developed for HIV research between institutions in the US and the Latin American and the Caribbean (LAC) region, the US National Cancer Institute (NCI) initiated ULACNet, a new Cooperative Agreement clinical trials network in 2019.
Methods: ULACNet comprises of three Partnership Centers each led by US-based institutions (University of California San Francisco, Weill Medical College of Cornell University, and Fred Hutchinson Cancer Research Center), working collaboratively with US and LAC institutions and with the NCI to develop and conduct multicenter prevention clinical trials focused on filling key scientific gaps and evaluating novel interventions.
Results: ULACNet encompasses six countries (US, Mexico, Puerto Rico, Brazil, Peru, and Dominican Republic), twenty partner institutions, and over 100 collaborating scientific investigators, clinical and public health practitioners, research staff, and patient advocates. ULACNet will collaboratively conduct nine prevention clinical trials (two prophylactic HPV vaccine trials in adults and perinatally-HIV infected adolescents, three trials for clinical validation of molecular biomarkers and imaging technologies for screening and triage, two candidate HPV therapeutic vaccine trials, and two trials of topical therapeutic agents). Facilitation across network partners is achieved via a Coordinating Committee and three Working Groups (focused on HPV testing and screening, precancer treatment, and recruitment and retention activities).
Conclusion: ULACNet seeks to leverage established academic global health partnerships to conduct high quality collaborative clinical trials to inform clinical practice and ultimately reduce the burden of highly preventable HPV-related cancers in persons living with HIV worldwide.
Citation Format: Emma Brofsky, Margaret House, Brandy Heckman-Stoddard, Mostafa Nokta, Satish Gopal, Vikrant Sahasrabuddhe. Development of International Cancer Research Partnerships Through the NCI US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet) [abstract]. In: Proceedings of the 9th Annual Symposium on Global Cancer Research; Global Cancer Research and Control: Looking Back and Charting a Path Forward; 2021 Mar 10-11. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2021;30(7 Suppl):Abstract nr 20.
Collapse
Affiliation(s)
- Emma Brofsky
- 1National Cancer Institute, Division of Cancer Prevention,
| | - Margaret House
- 2National Cancer Institute, Division of Cancer Prevention,
| | | | - Mostafa Nokta
- 2National Cancer Institute, Division of Cancer Prevention,
| | - Satish Gopal
- 3National Cancer Institute, Center for Global Health
| | | |
Collapse
|
6
|
Guerrieri-Gonzaga A, Serrano D, Thomas P, Crew KD, Kumar NB, Gandini S, Vornik LA, Lee J, Cagnacci S, Vicini E, Accornero CA, D'Amico M, Guasone F, Spinaci S, Webber TB, Brown PH, Szabo E, Heckman-Stoddard B, Bonanni B. Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial. Contemp Clin Trials 2021; 107:106498. [PMID: 34216815 PMCID: PMC8429140 DOI: 10.1016/j.cct.2021.106498] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/16/2021] [Accepted: 06/28/2021] [Indexed: 11/18/2022]
Abstract
Introduction: Aromatase inhibitors are effective in lowering breast cancer incidence among postmenopausal women, but adverse events represent a barrier to their acceptability and adherence as a preventive treatment. This study aims to assess whether lowering exemestane schedule may retain biological activity while improving tolerability in breast cancer patients. Methods/design: We are conducting a, pre-surgical, non-inferiority phase IIb study in postmenopausal women with newly diagnosed estrogen receptor-positive breast cancer. Participants are randomized to receive either exemestane 25 mg/day or 25 mg/three times-week or once a week for 4 to 6 weeks prior to surgery. The primary endpoint is the percentage change of serum estradiol concentration between baseline and surgery comparing the three arms. Sample size of 180 women was calculated assuming a 6% non-inferiority of the percent change of estradiol in the lower dose arms compared with the 80% decrease predicted in the full dose arm, with 80% power and using a one-sided 5% significance level and a two-sample t-test. Main secondary outcomes are: safety; change in Ki-67 in cancer and adjacent pre-cancer tissue, circulating sex hormones, adipokines, lipid profile, insulin and glucose changes, in correlation with drug and metabolites concentrations. Results and discussion: The present paper is focused on methodology and operational aspects of the study. A total of 180 participants have ben enrolled. The trial is still blinded, and the analyses are ongoing. Despite the short term duration, results may have relevant implications for clinical management of women at increased risk of developing a ER positive breast cancer.
Collapse
Affiliation(s)
| | | | | | | | - Nagi B Kumar
- Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
| | - Sara Gandini
- European Institute of Oncology IRCCS, Milan, Italy
| | - Lana A Vornik
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - Jack Lee
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | | | - Elisa Vicini
- European Institute of Oncology IRCCS, Milan, Italy
| | | | | | | | | | | | - Powel H Brown
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - Eva Szabo
- Division of Cancer Prevention, NCI, Bethesda, MD, USA
| | | | | |
Collapse
|
7
|
Sauter ER, Heckman-Stoddard B. Metabolic Surgery and Cancer Risk: An Opportunity for Mechanistic Research. Cancers (Basel) 2021; 13:cancers13133183. [PMID: 34202319 PMCID: PMC8268861 DOI: 10.3390/cancers13133183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 06/22/2021] [Indexed: 12/19/2022] Open
Abstract
Simple Summary Metabolic (bariatric) surgery (MBS) provides the greatest maximum and sustained weight loss among individuals who are morbidly obese. It is more effective than lifestyle interventions in improving or eliminating type 2 diabetes mellitus (T2DM) and in decreasing cardiovascular (CV) risk. Preclinical studies have been conducted to investigate the mechanisms by which MBS leads to the benefits in T2DM and CV risk. In this review, we describe the emerging evidence that MBS may also impact cancer risk and mortality, and whom may benefit most. We describe the long term involvement and commitment of the National Institutes of Health in obesity research in general and MBS in particular. We outline the need for additional research to understand the mechanism(s) by which MBS may influence cancer, since these mechanism(s) are currently unknown. Abstract Metabolic (bariatric) surgery (MBS) is recommended for individuals with a BMI > 40 kg/m2 or those with a BMI 35–40 kg/m2 who have one or more obesity related comorbidities. MBS leads to greater initial and sustained weight loss than nonsurgical weight loss approaches. MBS provides dramatic improvement in metabolic function, associated with a reduction in type 2 diabetes mellitus and cardiovascular risk. While the number of MBS procedures performed in the U.S. and worldwide continues to increase, they are still only performed on one percent of the affected population. MBS also appears to reduce the risk of certain obesity related cancers, although which cancers are favorably impacted vary by study, who benefits most is uncertain, and the mechanism(s) driving this risk reduction are mostly speculative. The goal of this manuscript is to highlight (1) emerging evidence that MBS influences cancer risk, and that the potential benefit appears to vary based on cancer, gender, surgical procedure, and likely other variables; (2) the role of the NIH in MBS research in T2DM and CV risk for many years, and more recently in cancer; and (3) the opportunity for research to understand the mechanism(s) by which MBS influences cancer. There is evidence that women benefit more from MBS than men, that MBS may actually increase the risk of colorectal cancer in both women and men, and there is speculation that the benefit in cancer risk reduction may vary according to which MBS procedure an individual undergoes. Herein, we review what is currently known, the historical role of government, especially the National Institutes of Health (NIH), in driving this research, and provide suggestions that we believe could lead to a better understanding of whether and how MBS impacts cancer risk, which cancers are impacted either favorably or unfavorably, the role of the NIH and other research agencies, and key questions to address that will help us to move the science forward.
Collapse
|
8
|
Lee O, Pilewskie M, Karlan S, Tull MB, Benante K, Xu Y, Blanco L, Helenowski I, Kocherginsky M, Yadav S, Hosseini O, Hansen N, Bethke K, Muzzio M, Troester MA, Dimond E, Perloff M, Heckman-Stoddard B, Khan SA. Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double-Blind, Placebo-Controlled Phase II Trial. Clin Pharmacol Ther 2021; 109:728-738. [PMID: 32996592 PMCID: PMC8388824 DOI: 10.1002/cpt.2041] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Accepted: 08/25/2020] [Indexed: 12/20/2022]
Abstract
Oral breast cancer prevention medications entail systemic exposure, limiting acceptance by high-risk women. Delivery through the breast skin, although an attractive alternative, requires demonstration of drug distribution throughout the breast. We conducted a randomized double-blind, placebo-controlled phase II clinical trial comparing telapristone acetate, a progesterone receptor antagonist, administered orally (12 mg/day) or transdermally (12 mg/breast) for 4 ± 1 weeks to women planning mastectomy. Plasma and tissue concentrations, measured at five locations in the mastectomy specimen using liquid chromatography tandem mass spectrometry were compared. In 60 evaluable subjects, median drug concentration (ng/g tissue) was 103 (interquartile range (IQR): 46.3-336) in the oral vs. 2.82 (IQR: 1.4-5.5) in the transdermal group. Despite poor dermal permeation, within-breast drug distribution pattern was identical in both groups (R2 = 0.88, P = 0.006), demonstrating that transdermally and orally delivered drug is distributed similarly through the breast, and is strongly influenced by tissue adiposity (P < 0.0001). Other skin-penetrant drugs should be tested for breast cancer prevention.
Collapse
Affiliation(s)
- Oukseub Lee
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Melissa Pilewskie
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Scott Karlan
- Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Mary B Tull
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Kelly Benante
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Yanfei Xu
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Luis Blanco
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Irene Helenowski
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Masha Kocherginsky
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Shivangi Yadav
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Omid Hosseini
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Nora Hansen
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Kevin Bethke
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Miguel Muzzio
- Analytical Chemistry Division, Illinois Institute of Technology Research Institute, Chicago, Illinois, USA
| | - Melissa A Troester
- Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Eileen Dimond
- National Cancer Institute Division of Cancer Prevention, Bethesda, Maryland, USA
| | - Marjorie Perloff
- National Cancer Institute Division of Cancer Prevention, Bethesda, Maryland, USA
| | | | - Seema A Khan
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| |
Collapse
|
9
|
Ramirez-Pena E, Hussey S, Negoita S, Heckman-Stoddard B. Abstract PS7-37: Learning from breast cancer clinical trials how to capture recurrence estimates for North American cancer registries: A systematic review. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps7-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There are currently approximately 3.5 million breast cancer survivors in the U.S. This number will continue to rise due to the medical and scientific advances that have improved diagnostic tools and standards of care for women treated for breast cancer. The increasing number of breast cancer survivors also means that the population at risk for cancer recurrence will increase. Cancer recurrence is defined as a cancer that was treated, reduced to undetectable levels, and later returned either locally, regionally, or distantly. After a recurrence diagnosis, patients’ experience reduced health outcomes and quality of life as well as the financial burden of additional treatments. Post-treatment surveillance strategies are critical for the early detection of recurrences so that interventions can be more effective at ensuring long term survival and quality of life. Currently, risk factors for breast cancer recurrence are not well understood in part due to limited population level data in cancer registries world-wide. The clinical endpoints that provide recurrence estimates are disease free survival (DFS), relapse free survival (RFS), and time to recurrence (TTR). Studies that provide recurrence estimates are limited to clinical trials (which lack diversity and represent less than 5% of cancer patients) and prospective cohorts that follow patients for a defined number of years. Currently, population-based cancer registries in North America do not collect recurrence data from patients that would allow the calculation of DFS, RFS, and TTR. The absence of population level data has limited the understanding of cancer patients’ individual risks and evidence-based recommendations for recurrence prevention strategies. Moreover, recurrence data on cancers with long term latency (greater than 5-10 years) such as estrogen receptor positive breast cancer are limited.Purpose: We seek to identify which data elements and surveillance strategies are collected for recurrence data in breast cancer clinical trials. Our long-term goal is to implement these data elements into the Surveillance, Epidemiology, and End Results (SEER) program to facilitate the calculation of breast cancer recurrence estimates at the U.S. population level.Methods: We performed a systematic literature review evaluating phase II-IV clinical trials, their reported clinical outcomes, surveillance strategies, and their diagnostic tests that confirm recurrence. We used PubMed, clinicaltrials.gov, EMBASE, and the Cochrane Library for search terms “recurrence”, “relapse”, “recurrence free survival”, “surgery”, “adjuvant therapy” in breast cancer for our literature search. Inclusion criteria included clinical trials with published results, trials that compared outcomes of surgical resections, surgery with adjuvant treatments, or multiple adjuvant treatments. We included trials that provided DFS, RFS, TTR, recurrence rate, recurrence free interval, progression free survival, and time to progression. We excluded trials that did not provide recurrence estimates and those that performed recurrence modeling.Conclusion: From our review, we identified data elements and recurrence estimates for breast cancer that are collected in clinical trials but are not included in North American registries. New data elements need to be included in North American cancer registries to calculate population-based estimates for recurrence.
Citation Format: Esmeralda Ramirez-Pena, Sarah Hussey, Serban Negoita, Brandy Heckman-Stoddard. Learning from breast cancer clinical trials how to capture recurrence estimates for North American cancer registries: A systematic review [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-37.
Collapse
|
10
|
O'Shea AE, Clifton GT, Qiao N, Heckman-Stoddard B, Wojtowicz M, Dimond E, Bedrosian I, Weber D, Husband A, Pastorello R, Vornik L, Peoples G, Mittendorf EA. Abstract PD11-09: Vadis trial: Phase II trial of nelipepimut-s peptide vaccine in women with DCIS of the breast. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-pd11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Peptide cancer vaccines may be most effective when used in earlier stage cancers or pre-cancers where systemic and tumor microenvironmental immune suppression are less profound. Nelipepimut-S (NPS) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) is a vaccine comprised of a human leukocyte antigen (HLA) restricted peptide from the extracellular domain of the HER2 protein (E75) combined with GM-CSF. We have completed a randomized phase II trial of preoperative vaccination with NPS+GM-CSF vs. GM-CSF alone with the primary outcome being NPS-specific cytotoxic T lymphocyte (CTL) responses.
Methods: HLA-A2 positive, DCIS patients were enrolled and randomized to either NPS+GM-CSF vs GM-CSF alone. The patients received two vaccinations prior to surgery at 2-week intervals. The number of NPS-specific CTL was measured at specified intervals (pre-vaccination, time of surgery, 1 month (+/- 7 days) post-op, and 3 months (+/- 7 days) post-op) using a flow cytometry-based dextramer assay. Differences in NPS-specific CTL responses between the two groups and between baseline pre-vaccination and 1-month post-op were analyzed using either a two-sample t-test or Wilcoxon rank sum test, when appropriate. The incidence and severity of adverse events, graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03, were recorded and compared between treatment groups.
Results: 45 patients were registered; 7 withdrew consent, 1 opted for surgery at an external facility, 20 were ineligible due to negative HLA-A2, and 4 failed screening for other reasons, leaving 13 patients enrolled. The 13 patients were randomized (2:1) into treatment groups, with nine patients receiving NPS+GM-CSF and four patients receiving GM-CSF alone. The two groups were well-matched for age; however, the GM-CSF alone group had higher percentages of African American (50% vs. 22%) and Hispanic (25% vs. 11%) patients as compared to the NPS+GM-CSF group. In general, vaccination was well-tolerated with similar treatment-related toxicity profiles in the NPS+GM-CSF vs GM-GSF groups (Grade 1 - 93.3% vs. 89.3%, Grade 2 - 6.7% vs. 10.7%, respectively). The mean NPS-specific CTL% in the NPS+GM-CSF group at 1-month post-op was double that of the GM-CSF alone group (0.10 +/- 0.12% vs. 0.05 +/- 0.08, p=0.70). In addition, between baseline pre-vaccination and 1-month post-op, the NPS+GM-CSF group experienced an 11-fold increase in percentage of NPS-specific CTL (0.01 +/- 0.02% vs. 0.11 +/- 0.12%) as compared to only a 2.25-fold increase of NPS-specific CTL in the GM-CSF alone group (0.04 +/- 0.07% vs. 0.09 +/- 0.15%).
Conclusions: NPS+GM-CSF is safe and well-tolerated when given preoperatively to patients with DCIS. In HLA-A2 positive patients with DCIS, a single inoculation with NPS+GM-CSF can induce in vivo immunity and a continued antigen-specific T-cell response one month post-surgery. This data provides support for further testing of NPS+GM-CSF in the neoadjuvant and adjuvant settings in an attempt to prevent invasive recurrence in DCIS.
Citation Format: Anne E O'Shea, Guy T Clifton, Na Qiao, Brandy Heckman-Stoddard, Malgorzata Wojtowicz, Eileen Dimond, Isabelle Bedrosian, Diane Weber, Alex Husband, Ricardo Pastorello, Lana Vornik, George Peoples, Elizabeth A Mittendorf. Vadis trial: Phase II trial of nelipepimut-s peptide vaccine in women with DCIS of the breast [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD11-09.
Collapse
Affiliation(s)
| | | | - Na Qiao
- 2The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | - Diane Weber
- 2The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Lana Vornik
- 2The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | |
Collapse
|
11
|
Thomas PS, Patel AB, Liu D, Lee JJ, Khan S, Muzzio M, Contreras A, Vornik L, Dimond EP, Perloff M, Heckman-Stoddard B, Brown PH. Abstract PS8-12: Interim analysis of a phase I dose escalation study of topical bexarotene in women at high risk for breast cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps8-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer prevention with anti-estrogens, including tamoxifen, raloxifene, and exemestane, has been shown to reduce the incidence of hormone receptor-positive breast cancer. However, agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene are vitamin A analogues that have been shown to be involved in cell differentiation, growth, and apoptosis. In preclinical mouse models that develop ER-negative breast cancers, bexarotene showed a significant reduction in mammary tumor development. Oral bexarotene has been evaluated in BRCA mutation carriers and significant decreases in cyclin D1 were noted in breast cells suggesting biological activity of bexarotene on breast tissue. Systemic side effects of hyperlipidemia and hypothyroidism were also found. Data from chemoprevention studies with topical 4-hydroxytamoxifen support the concept of topical agents penetrating into the breast tissue and exhibiting biological activity. We hypothesize that topical bexarotene can be applied to the breast as a prevention agent with penetration into the breast tissue and without subsequent systemic side effects as seen with oral bexarotene. Methods: Women at high risk for breast cancer were recruited and assigned to escalating doses of 1% topical bexarotene: 10mg (1ml) every other day, 10mg (1ml) daily and 20mg (2ml) daily for 4 weeks. Cohorts of 3-4 participants were enrolled and fully evaluated through 4 weeks prior to enrolling the next cohort. Each dose level enrolled a maximum of 10 participants. The primary endpoint of the study was to determine the recommended phase II dose of topical bexarotene 1% gel for evaluation in healthy at-risk women. Dose Limiting Toxicity (DLT) was defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 3 or greater adverse event related to the study drug. A grade 2 skin adverse event that recurs and persists for at least 3 days is also a DLT. The Maximum Tolerated Dose (MTD) was defined as the highest dose level at which no more than 2 participants experience a DLT among 10 participants treated. Once the MTD was determined, interim biomarker analysis will be completed to assess bexarotene levels in serum and tissue samples. An expansion cohort of an additional 10 patients will be recruited at the MTD to further evaluate safety and toxicity. Secondary endpoints include serum bexarotene level, tissue bexarotene levels, and changes in thyroid function tests, lipid profile, and calcium. Results: Ten women were enrolled at the dose level of 10mg every other day and 9/10 participants experienced Grade 1 skin related events at the application site. Two participants reported Grade 2 skin related events at the application site but did not last long enough to be considered DLTs. Four women were enrolled at the second dose level of 10mg daily and 3/4 experience Grade 2 skin related events including 2 DLTs which stopped accrual to the study. Therefore, the MTD was determined to be 10mg every other day. No laboratory abnormalities were noted across either dose level and no grade 3 or 4 adverse events were reported. Conclusion: Maculopapular rash at treatment site was the most common adverse event related to study drug and resolved with discontinuation. Analysis is ongoing to assess bexarotene drug levels in serum and breast tissue samples.
Citation Format: Parijatham S Thomas, Anisha B Patel, Diane Liu, J. Jack Lee, Seema Khan, Miguel Muzzio, Alejandro Contreras, Lana Vornik, Eileen P Dimond, Marjorie Perloff, Brandy Heckman-Stoddard, Powel H Brown. Interim analysis of a phase I dose escalation study of topical bexarotene in women at high risk for breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS8-12.
Collapse
Affiliation(s)
| | - Anisha B Patel
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - Diane Liu
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - J. Jack Lee
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | - Lana Vornik
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | - Powel H Brown
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
12
|
Samimi G, Sathyamoorthy N, Tingen CM, Mazloomdoost D, Conroy J, Heckman-Stoddard B, Halvorson LM. Report of the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored workshop: gynecology and women's health-benign conditions and cancer. Am J Obstet Gynecol 2020; 223:796-808. [PMID: 32835714 DOI: 10.1016/j.ajog.2020.08.049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 07/31/2020] [Accepted: 08/19/2020] [Indexed: 12/14/2022]
Abstract
The Division of Cancer Prevention and the Division of Cancer Biology at the National Cancer Institute and the Gynecologic Health and Disease Branch in the National Institute of Child Health and Human Development organized a workshop in April 2019 to explore current insights into the progression of gynecologic cancers from benign conditions. Working groups were formed based on 3 gynecologic disease types: (1) Endometriosis or Endometrial Cancer and Endometrial-Associated Ovarian Cancer, (2) Uterine Fibroids (Leiomyoma) or Leiomyosarcoma, and (3) Adenomyosis or Adenocarcinoma. In this report, we highlight the key questions and current challenges that emerged from the working group discussions and present potential research opportunities that may advance our understanding of the progression of gynecologic benign conditions to cancer.
Collapse
|
13
|
Arun BK, Gierach G, Scoggins ME, Khan S, Rao SS, Garber J, Raza S, Kumar NB, Han HH, Heine J, Niell B, Chalasani P, Fitzpatrick K, Wilke LG, Fowler A, Beckwith HC, Mays C, Abutaseh S, Vornik L, Lee O, Dimond E, Perloff M, Liu D, Lee JJ, Brown P, Heckman-Stoddard B. Abstract OT3-15-02: A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-ot3-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tamoxifen uptake for risk reduction has remained low due to concerns about toxicity despite the efficacy and effectiveness data available. Studies of tamoxifen in the adjuvant and preventive setting have demonstrated that a decline in mammographic density (MD) of approximately 10% is consistently associated with better outcomes. Additionally, MD is one of the strongest independent predictors of breast cancer risk, apart from older age and BRCA1/2 mutation, among women. 4-hydroxytamoxifen topical gel (4-OHT) is a transdermal agent, shown in preliminary studies to be well-tolerated with similar decreases in Ki-67 to oral tamoxifen in presurgical DCIS studies and significant drug concentration in breast parenchyma but very low levels in the systemic circulation. This study examines changes in MD, a potential surrogate biomarker of prevention activity, as the primary endpoint for this one-year early-phase prevention trial using 4-OHT gel in high risk women.
Trial design: Multicenter, randomized, placebo-controlled study of 4-OHT gel (2mg per breast) versus placebo in 152 women with heterogeneously or extremely dense breast tissue for 12 months using standard of care imaging, stratified by enrollment site and baseline breast density category. The primary objective of this study is to evaluate the change in percent MD (using Cumulus software) from baseline to the week 52 in women applying 4 mg (2mg per breast) 4-OHT gel versus placebo. The secondary objectives are to compare the Cumulus vs Volpara breast density measurement methods; evaluate the percentage of women with lowering of BIRADS density; estimate percentage of women with ≥ 10% absolute decrease in quantitative MD percentage; explore patient reported experience assessed by BESS questionnaire; laboratory toxicity assessment (F VIII, vWB factor, SHBG, lipid profile); compare the 2D vs. 3D breast density measurement methods to estimate percent change in mammographic breast density; evaluate serum measurements of parent drug and related metabolite levels and factors related to 4-OHT exposures, such as IGF pathway members, CRP, estradiol, and 4-OHT; collect tissue for biomarkers (among women undergoing optional pre- and post-treatment biopsies); examine the persistence in change of mammographic density one year after 4-OHT vs. placebo gel application has stopped.
Eligibility criteria: Inclusion: Women age 40-69 years, or less than 40 years if 5-year breast cancer Gail risk is greater than/equal to 1.66%; heterogeneously or extremely dense breast tissue based on mammography. Exclusion: abnormal uterine bleeding, or prior diagnosis of endometrial hyperplasia, endometrial polyps, or endometrial cancer; prior use of SERMS and AIs, except for a maximum of 3 months and at least 12 months prior.
Statistical methods: Considering an attrition rate of 15%, 128 evaluable women are expected to have both baseline and 52-week measurements of percent MD. With 64 women in each group, there is 80% power to detect a decrease of 6% in the 4-OHT group versus 2% in the placebo group with a common standard deviation of 8% using a two-sided t-test with a significance level of 0.05. Study accrual: Activated January 2018, as of July 1, 2019, 92 patients have been recruited and 79 were randomized.
Citation Format: Banu K. Arun, Gretchen Gierach, Marion E Scoggins, Seema Khan, Sandra S Rao, Judy Garber, Sughra Raza, Nagi B. Kumar, Heather H Han, John Heine, Bethany Niell, Pavani Chalasani, Kimberly Fitzpatrick, Lee G Wilke, Amy Fowler, Heather C Beckwith, Carrie Mays, Saba Abutaseh, Lana Vornik, Oukseub Lee, Eileen Dimond, Marjorie Perloff, Diane Liu, J. Jack Lee, Powell Brown, Brandy Heckman-Stoddard. A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT3-15-02.
Collapse
Affiliation(s)
- Banu K. Arun
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | | | - Nagi B. Kumar
- 5Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Heather H Han
- 5Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - John Heine
- 5Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Bethany Niell
- 5Moffitt Cancer Center, University of South Florida, Tampa, FL
| | | | | | | | | | | | - Carrie Mays
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | - Saba Abutaseh
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | - Lana Vornik
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | | | | | | | - Diane Liu
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | - J. Jack Lee
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | - Powell Brown
- 1University of Texas - MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
14
|
Benante KA, Xu Y, Tull MB, Segura AJ, Alber KM, Kalinichenko K, Hou L, Jovanovic B, Perloff M, Heckman-Stoddard B, Dimond E, Khan SA. Abstract OT1-04-01: A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Ductal carcinoma in situ (DCIS) is diagnosed in 60,000 women annually in the US. TAM is proven to reduce risk of local recurrence and new primary breast cancer in women with estrogen receptor (ER) positive DCIS. However, acceptance of TAM has been low, primarily because of toxicity related to systemic exposure. Local delivery to the breast is an attractive alternative since low systemic levels could minimize toxicity. 4-OHT is an active metabolite of TAM. When formulated as a gel and applied to the breast skin, it is well tolerated, and results in 4-OHT breast tissue drug levels comparable oral TAM. In small pilot studies, its anti-proliferative effects on invasive breast tumors and DCIS are also similar to oral TAM [Lee O, et al. PMID 25028506]. The goal of our study is to validate these results in preparation for a Phase III trial of 4-OHT gel in comparison to oral TAM.
Methods
We are conducting a randomized, double-blinded, placebo-controlled, Phase IIB pre-surgical trial to demonstrate that daily application of 4-OHT gel will result in a reduction in the Ki-67 labeling index of DCIS lesions that is not inferior to that seen in women receiving daily oral TAM 20 mg daily. Ki-67 of the base-line diagnostic core needle biopsy will be compared to that of the therapeutic surgical excision sample after oral TAM or 4-OHT gel for 8 ± 2 weeks. Secondary endpoints include changes in Oncotype DCIS-Score, IHC markers (CD68, COX2, p16), hormone levels, coagulation markers, drug concentration in the plasma and breast tissue, the fraction of women with no residual DCIS in the surgical sample, and experienced symptoms. 100 women (assuming 20% non-evaluable samples or compliance issues) with DCIS (10% ER-positive) will be enrolled across six institutions into two intervention arms: oral TAM 20 mg daily, placebo gel and 4-OHT gel 4mg daily (2mg/breast), placebo capsule. All participants will be evaluable for toxicity from their first dose. All samples from all participants who receive drug will be evaluated and included in the primary analysis, which will be based on intent to treat principle. To date 15 of 100 participants have been enrolled across six institutions including: Northwestern University in Chicago, IL, St. Elizabeth Healthcare in Edgewood, KY, Duke University Medical Center in Durham, NC, Cleveland Clinic in Cleveland, OH, Memorial Sloan Kettering Cancer Center in New York, NY, and Mayo Clinic in Rochester, MN. Since study open, 69 potential participants have been contacted, 52 did not consent for screening, 17consented for screening, 2 are pending consent, and 15 have started study intervention. The most common reasons potential participants chose not to consent are wanting to schedule surgery as soon as possible, attitudes toward medical research, and current use of a prohibited concomitant medication such as a potent inhibitor of tamoxifen metabolism or exogenous sex steroid.
Funding Source: NCI Contract # HHSN2612201200035I.
Citation Format: Benante KA, Xu Y, Tull MB, Segura AJ, Alber KM, Kalinichenko K, Hou L, Jovanovic B, Perloff M, Heckman-Stoddard B, Dimond E, Khan SA. A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-04-01.
Collapse
Affiliation(s)
- KA Benante
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - Y Xu
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - MB Tull
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - AJ Segura
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - KM Alber
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - K Kalinichenko
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - L Hou
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - B Jovanovic
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - M Perloff
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - B Heckman-Stoddard
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - E Dimond
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| | - SA Khan
- Northwestern University, Chicago, IL; National Institutes of Health, Bethesda, MD
| |
Collapse
|
15
|
Pinsky PF, Miller E, Heckman-Stoddard B, Minasian L. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort. Am J Obstet Gynecol 2018; 218:606.e1-606.e9. [PMID: 29630889 PMCID: PMC5970073 DOI: 10.1016/j.ajog.2018.03.031] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Revised: 02/21/2018] [Accepted: 03/24/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND Raloxifene and tamoxifen are Food and Drug Administration-approved for breast cancer risk reduction; in 2013, the US Preventive Services Task Force recommended these drugs for breast cancer risk reduction in high-risk women. Information on the use of raloxifene and tamoxifen for breast cancer risk reduction in the general population indicates that the risk is believed to be low; however, there is little literature. OBJECTIVE The purpose of this study was to assess the use of breast cancer risk reduction medications by breast cancer risk level in an older cohort of women. STUDY DESIGN Women who were enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were assessed for the use of raloxifene, tamoxifen, and other medications. The data sources for use of the drugs were a mailed medication use questionnaire in 2013 and linked Medicare Part D claims files from 2010-2014. Estimated breast cancer risk within 5 years was assessed with the use of the modified Gail model and self-reported breast cancer risk factors; comorbidities were assessed through a questionnaire. RESULTS A total of 22,235 women completed the medication use questionnaire; of these, 13,640 women (61%) had linked Part D data. In 2013, 45% of the women were 65-74 years old, and 55% of the women were 75-84 years old. From the medication use questionnaire, raloxifene use (past month) was 1.8%, 2.5%, and 4.0% for women with breast cancer risk within 5 years of <1.66%, 1.66-3.0%, and ≥3%, respectively (probability value trend, <.0001). From Part D, for any use during the period among women with coverage, raloxifene rates were 3.3%, 4.0%, and 6.6% for the 3 categories for breast cancer risk within 5 years (probability value trend, <.0001); use was 7.4% and 3.3% in women with and without osteoporosis, respectively. Raloxifene use significantly decreased from 2010-2014, and specifically from 2012-2014, both for all women and for women with breast cancer risk within 5 years of ≥3%. Tamoxifen use from Part D was 0.36%, 0.45%, and 0.85% for the 3 categories for breast cancer risk within 5 years (probability value trend, .009). CONCLUSION Raloxifene use was low overall but increased modestly with breast cancer risk, and usage decreased from 2010-2014. Tamoxifen use was very low.
Collapse
Affiliation(s)
- Paul F Pinsky
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD.
| | - Eric Miller
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Brandy Heckman-Stoddard
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Lori Minasian
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
16
|
Mittendorf EA, Plitas G, Garber J, Crew K, Heckman-Stoddard B, Wojtowicz M, Vornik L, Peoples GE, Brown PH. Abstract OT3-01-04: VADIS trial: Phase II trial of the nelipepimut-S peptide v
accine in women with DC IS of the breast. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our group has been investigating vaccination strategies in breast cancer. Specifically, we have been evaluating HER2-derived peptide vaccines including nelipepimut-S+GM-CSF administered adjuvantly to breast cancer patients who have been rendered disease-free with standard of care therapy but are at high risk for recurrence. Early phase clinical trials showed an approximately 50% reduction in relative recurrence risk in vaccinated patients. Based on these data, nelipepimut-S+GM-CSF is being evaluated in a phase III registration trial. Having shown the vaccine to be safe, effective in stimulating an antigen-specific immune response and potentially having clinical efficacy in the setting of secondary prevention, the current study was initiated to evaluate vaccination in DCIS patients. This trial represents an initial step to move the vaccine into the primary prevention setting.
Trial Design: Phase II, randomized, single-blind study. Patients will be randomized 2:1 to receive vaccine or GM-CSF alone. After enrollment, patients will receive 3 inoculations administered every other week preoperatively followed by surgery then completion of the vaccination series (3 additional inoculations) in the adjuvant setting.
Eligibility: The trial will enroll pre- or post-menopausal women with a diagnosis of DCIS made by core biopsy. The area of radiographic abnormality must measure at least 1 cm. Because the vaccine is a MHC class I, CD8+ T cell-eliciting vaccine, it is HLA restricted, and patients must be HLA-A2+ to enroll. Participants must also have an ECOG performance status <2, adequate cardiac, kidney and liver function and be willing to comply with all study interventions and follow-up procedures.
Specific Aims: The trial's primary endpoint is to evaluate for nelipepimut-specific CD8+ T cells in the peripheral blood of vaccinated patients compared to patients receiving GM-CSF alone. Secondary endpoints include evaluating toxicity; determining the immune response in vivo by DTH, in vitro by evaluating for epitope spreading to other tumor antigens, and importantly in the tumor by assessing the degree of lymphocytic infiltration in surgically resected specimens. The extent of HER2 expression, Ki67 and cleaved caspase 3 in the resected specimen will also be assessed.
Statistical Methods: A total of 108 DCIS patients will be consented and screened for eligibility. 48 (45%) are expected to be HLA-A2 positive. These 48 patienst will be randomized 2:1 to vaccine or GM-CSF alone groups. Accounting for 10% attrition rate and for an approximately 5% non-evaluable sample rate, we expect to have 40 evaluable patients, 27 in the vaccine group and 13 in the GM-CSF alone group, that have baseline, pre-surgery, and post-surgery measures of nelipepimut-S-specific CD8+ T cells. We will have 82% power to detect a significant increase in nelipepimut-S-specific CD8+ T cells in the vaccine group versus the GM-CSF alone group.
Contact Info: The study is accruing at four sites to include Columbia University, Dana Farber Cancer Institute, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Additional information can be obtained from the overall study PI, Dr. Elizabeth Mittendorf (eamitten@mdanderson.org). NCT0236582.
Citation Format: Mittendorf EA, Plitas G, Garber J, Crew K, Heckman-Stoddard B, Wojtowicz M, Vornik L, Peoples GE, Brown PH. VADIS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-01-04.
Collapse
Affiliation(s)
- EA Mittendorf
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - G Plitas
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - J Garber
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - K Crew
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - B Heckman-Stoddard
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - M Wojtowicz
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - L Vornik
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - GE Peoples
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - PH Brown
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| |
Collapse
|
17
|
Lee O, Chatterton RT, Muzzio M, Page K, Jovanovic B, Helenowski I, Dunn B, Heckman-Stoddard B, Foster K, Shklovskaya J, Skripkauskas S, Bergan R, Khan SA. Abstract P1-09-07: Topical 4-OHT trial in women with DCIS of the breast: report of plasma and breast tissue concentration of tamoxifen metabolites. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-09-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Earlier studies have shown that 1–2mg of 4-hydroxytamoxifen (4–OHT) gel applied to the breast skin reduced cell proliferation in estrogen receptor (ER) positive invasive cancers to a similar degree as oral tamoxifen (TAM), with significantly lower plasma levels. We now report results of a Phase IIB pre-surgical window trial of women with DCIS, designed to obtain pilot data in early lesions. Our ultimate goal is to develop transdermal 4-OHT as an alternative to oral TAM for women at high risk for breast cancer and those with DCIS. The study was closed early because the manufacturer discontinued the drug supply, but remains blinded until all biomarker analysis is complete. Here we report the plasma and breast adipose tissue concentration of TAM metabolites from the topical 4-OHT gel group (4 mg) in comparison with the oral TAM group (20mg).
Methods: Women with DCIS were enrolled, and randomized to 4-OHT gel (4mg/day, 2mg per breast, E: Z isomers = 1:1,) or to oral (Z) TAM (20mg/day) for 4–10 weeks before surgery. Blood was collected on the day of surgery, and breast adipose tissue was collected at surgery. There were a total of 22 patients with matched blood and breast adipose tissue. The concentration of TAM metabolites in plasma and breast tissue was determined with liquid chromatography/tandem mass spectrometry. We assumed that the subjects with detectable N-desmethyl TAM (NDT) in plasma belong to the oral TAM group because NDT is not a product of 4-OHT metabolism. Under this assumption, 13 subjects were categorized into oral TAM group, and 9 subjects into the topical 4-OHT group. Wilcoxon rank-sum test was used for statistical analysis.
Results: The results are shown in the table. The concentration is presented as mean ± SD; the lowest quantitation limit (LQL) was 1 ng/mL for plasma, and 3 ng/g for tissue. TAM and its metabolites were found in the plasma of the presumed oral TAM group, with high levels of TAM and NDT. In the presumed 4-OHT gel group, only (Z) 4-OHT was found in the plasma although both (E) and (Z) forms were applied. The mean plasma level of 4-OHT in the gel group was 70% lower than the mean of 4-OHT in the oral TAM group (p = 0.004). In breast tissue, similar amounts of (E) and (Z) forms of 4-OHT were found in the 4-OHT gel group, with the (Z) 4-OHT level being equivalent to that in the oral TAM group (p = 0.48). Endoxifen was only found in the oral TAM group. We saw no evidence of further metabolic transformation of 4-OHT in the breast following topical administration.
Conclusions: With 4 mg of 4-OHT gel daily applied to the breasts of DCIS patients, the mean plasma level of 4-OHT was significantly lower and the mean breast tissue level of 4-OHT was similar to that in women taking oral TAM 20 mg daily, thus confirming the results from previous studies. We are still evaluating efficacy of topical 4-OHT in terms of reduction of cell proliferation (Ki67).
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-09-07.
Collapse
Affiliation(s)
- O Lee
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - RT Chatterton
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - M Muzzio
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - K Page
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - B Jovanovic
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - I Helenowski
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - B Dunn
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - B Heckman-Stoddard
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - K Foster
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - J Shklovskaya
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - S Skripkauskas
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - R Bergan
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - SA Khan
- Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD
| |
Collapse
|
18
|
Heckman-Stoddard B, Grubbs C, Johnson KA, Lubet R. Abstract A42: Doses of selective estrogen receptor modulations (SERMS) required for prevention and therapy of chemically induced mammary cancers. Cancer Prev Res (Phila) 2010. [DOI: 10.1158/1940-6207.prev-10-a42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Selective estrogen receptor modulators (SERMs) interfere with the activation of the estrogen receptor. SERMs have been shown to be effective for both treatment and prevention of breast cancer. Here we examine the ability of tamoxifen and arzoxifene, a more easily absorbed form of raloxifene, to prevent mammary tumors at a significantly lower dosage than those used for treatment. For prevention studies, female Sprague-Dawley rats (50 days of age) were injected with a single i.v. dose of MNU resulting in the development of multiple ER-positive mammary tumors beginning 7 weeks after carcinogen treatment. Rats were administered the preventive agent beginning five days after carcinogen administration. When the agents were tested at does varying between 0.15-3.3 ppm in the diet, both agents caused a dose dependent increase in preventive activity. The highest doses of tamoxifen (3.3 ppm) and arzoxifene (3.0 ppm) both decreased tumor multiplicity greater than 90%. Both of these doses are less than one-fifth the human equivalent dose (HED) based on standard FDA scaling factors. Both doses also resulted in substantial decreases in mammary gland development. These dosages were then used in a therapy setting to compare the efficacy. For these studies, MNU treated rats were allowed to develop their first palpable mammary tumor (70-150 mm2) before initiating treatment. Tumor growth or regression was followed by caliper measurements. Neither of the preventive doses of these SERMs exhibited therapeutic activity although substantially higher doses of tamoxifen (33 or 100 ppm) were relatively effective. These results are in contrast to our prior findings with other classes of agents (RXR agonists, EGFR inhibitors, and aromatase inhibitors) in which highly effective preventive doses were as effective as therapeutic doses in this model. These results demonstrate the unique dose differential regarding prevention and therapy with SERMs. Microarray analysis of tumors treated for 5 days with tamoxifen at doses of 3.3ppm or 100ppm reveals overlapping significant gene changes of similar magnitude in comparison to control treated tumors although there were significant gene changes seen at the therapeutic dose which were not observed at the lower dose. These studies raise two questions: 1) whether this class of agents might be used at significantly lower doses in a pure prevention setting as contrasted with a therapeutic setting where they were initially defined; 2) are there gene expression changes which might be used to help identify this differential dosing for prevention vs. therapy.
Citation Information: Cancer Prev Res 2010;3(12 Suppl):A42.
Collapse
|